Medical Affairs

The Value of a Medical Affairs Strategic Partnership: Meeting Today’s Challenges

As the healthcare landscape continues to shift, pharmaceutical companies are acknowledging that the way they’ve approached the development and commercialization of their therapies must also shift.

Solving for Today’s Challenges

The Bridge Between Clinical Development and Commercialization

By engaging in a Medical Affairs partnership with EVERSANA as early as Phase II, we are able to help:

Support the design of your ideal product profile that addresses unmet need.
Structure trials to meet the objectives of your product profile.
Define your product’s value
Collect data and drive subsequent insight generation
Develop the corresponding medical and commercial strategy

Why Our Medical Affairs Model Is Different

EVERSANA is disrupting the medical affairs services industry with the creation of an end-to-end integrated, customer-centric model that redefines scientific exchange to drive improved care pathways and optimize patient outcomes.

Unlike the traditional model – seen as a cost center, our model is strategic and directly impacting business KPIs.

Our Process Is Rooted in a Strong Foundation of Scientific Evidence and Strategy

EVERSANA’s Core Medical Affairs Capabilities

Phase II Through Commercialization

Medical Affairs Operational Excellence
Scientific Platform, Narrative and Core Foundational Content
Medical Strategy and Planning
Medical Information
Health economics and outcomes research/ Data, Evidence and Value Generation & Insights
Publications Planning and Data Dissemination
KOL Identification and Engagement
Clinical Trial Support: Scientific Exchange and P2P Education
Congress Activities
Omnichannel Dissemination Strategy and Planning

Phase III Through Commercialization

Field Medical

Phase IV Through Commercialization

Patient advocacy
Customer engagement and digital strategy

문의

Schedule a meeting today!

Against the Odds: Managing the Uncertainty of FDA Approval for Emerging Companies

Posted by Mike DeLaroche, Siddharth Agrawal on 10월 6, 202210/6/22

47% of FDA applications are delayed for resourceful larger pharma. The situation is even worse for emerging pharma, with 78% of FDA applications being delayed. Pharmaceutical companies have seen a steady and daunting rise in FDA approval delays for their new products over the past decade. From 2010-2021 the percentage of approved drugs referred to […]